Literature DB >> 28423289

Reevaluating Eligibility Criteria - Balancing Patient Protection and Participation in Oncology Trials.

Julia A Beaver1, Gwynn Ison1, Richard Pazdur1.   

Abstract

Entities:  

Mesh:

Year:  2017        PMID: 28423289     DOI: 10.1056/NEJMp1615879

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  26 in total

Review 1.  Barriers to accrual and enrollment in brain tumor trials.

Authors:  Eudocia Q Lee; Ugonma N Chukwueke; Shawn L Hervey-Jumper; John F de Groot; Jose Pablo Leone; Terri S Armstrong; Susan M Chang; David Arons; Kathy Oliver; Kay Verble; Al Musella; Nicole Willmarth; Brian M Alexander; Amanda Bates; Lisa Doherty; Evanthia Galanis; Sarah Gaffey; Thomas Halkin; Bret E Friday; Maryam Fouladi; Nancy U Lin; David Macdonald; Minesh P Mehta; Marta Penas-Prado; Michael A Vogelbaum; Solmaz Sahebjam; David Sandak; Martin van den Bent; Michael Weller; David A Reardon; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2019-09-06       Impact factor: 12.300

2.  Flexibility and innovation in the FDA's novel regulatory approval strategies for hematologic drugs.

Authors:  Ann T Farrell; Kirsten B Goldberg; Richard Pazdur
Journal:  Blood       Date:  2017-08-03       Impact factor: 22.113

Review 3.  Future cancer research priorities in the USA: a Lancet Oncology Commission.

Authors:  Elizabeth M Jaffee; Chi Van Dang; David B Agus; Brian M Alexander; Kenneth C Anderson; Alan Ashworth; Anna D Barker; Roshan Bastani; Sangeeta Bhatia; Jeffrey A Bluestone; Otis Brawley; Atul J Butte; Daniel G Coit; Nancy E Davidson; Mark Davis; Ronald A DePinho; Robert B Diasio; Giulio Draetta; A Lindsay Frazier; Andrew Futreal; Sam S Gambhir; Patricia A Ganz; Levi Garraway; Stanton Gerson; Sumit Gupta; James Heath; Ruth I Hoffman; Cliff Hudis; Chanita Hughes-Halbert; Ramy Ibrahim; Hossein Jadvar; Brian Kavanagh; Rick Kittles; Quynh-Thu Le; Scott M Lippman; David Mankoff; Elaine R Mardis; Deborah K Mayer; Kelly McMasters; Neal J Meropol; Beverly Mitchell; Peter Naredi; Dean Ornish; Timothy M Pawlik; Jeffrey Peppercorn; Martin G Pomper; Derek Raghavan; Christine Ritchie; Sally W Schwarz; Richard Sullivan; Richard Wahl; Jedd D Wolchok; Sandra L Wong; Alfred Yung
Journal:  Lancet Oncol       Date:  2017-10-31       Impact factor: 41.316

4.  An Analysis of Recent FDA Oncology Scientific Publications.

Authors:  Julie A Schneider; Andrew C Miklos; James Onken; Yutao Gong; Anna Maria Calcagno; Gideon M Blumenthal; Richard Aragon; Richard Pazdur
Journal:  Oncologist       Date:  2019-11-26

Review 5.  HIV-Associated Cancers and Related Diseases.

Authors:  Robert Yarchoan; Thomas S Uldrick
Journal:  N Engl J Med       Date:  2018-03-15       Impact factor: 91.245

6.  Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials.

Authors:  Narjust Duma; Sejal M Kothadia; Tariq U Azam; Siddhartha Yadav; Jonas Paludo; Jesus Vera Aguilera; Miguel Gonzalez Velez; Thorvardur Ragnar Halfdanarson; Julian R Molina; Joleen M Hubbard; Ronald S Go; Aaron S Mansfield; Alex A Adjei
Journal:  Oncologist       Date:  2018-11-09

7.  An Analysis of Recent FDA Oncology Scientific Publications.

Authors:  Julie A Schneider; Andrew C Miklos; James Onken; Yutao Gong; Anna Maria Calcagno; Gideon M Blumenthal; Richard Aragon; Richard Pazdur
Journal:  Oncologist       Date:  2019-11-26

8.  Exploring New Therapeutic Pathways in Pulmonary Hypertension. Metabolism, Proliferation, and Personalized Medicine.

Authors:  M Patricia George; Mark T Gladwin; Brian B Graham
Journal:  Am J Respir Cell Mol Biol       Date:  2020-09       Impact factor: 6.914

Review 9.  Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

Authors:  Gita Thanarajasingam; Lori M Minasian; Frederic Baron; Franco Cavalli; R Angelo De Claro; Amylou C Dueck; Tarec C El-Galaly; Neil Everest; Jan Geissler; Christian Gisselbrecht; John Gribben; Mary Horowitz; S Percy Ivy; Caron A Jacobson; Armand Keating; Paul G Kluetz; Aviva Krauss; Yok Lam Kwong; Richard F Little; Francois-Xavier Mahon; Matthew J Matasar; María-Victoria Mateos; Kristen McCullough; Robert S Miller; Mohamad Mohty; Philippe Moreau; Lindsay M Morton; Sumimasa Nagai; Simon Rule; Jeff Sloan; Pieter Sonneveld; Carrie A Thompson; Kyriaki Tzogani; Flora E van Leeuwen; Galina Velikova; Diego Villa; John R Wingard; Sophie Wintrich; John F Seymour; Thomas M Habermann
Journal:  Lancet Haematol       Date:  2018-06-18       Impact factor: 18.959

10.  QTc Interval-Prolonging Medications Among Patients With Lung Cancer: Implications for Clinical Trial Eligibility and Clinical Care.

Authors:  Tri Le; Hui Yang; Sawsan Rashdan; Mark S Link; Vlad G Zaha; Carlos Alvarez; David E Gerber
Journal:  Clin Lung Cancer       Date:  2019-11-25       Impact factor: 4.785

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.